Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
In this report, we will review key insights derived from the development of mRNA-based COVID-19 vaccines and how they can be applied to accelerate progress in the manufacture of mRNA vaccines and therapeutics moving forward, focusing on the following:
• The unique attributes of mRNA vaccine development
• The planning paradigm shift to address major process
challenges and streamline workflow
• Global supply chain implications and the investments and innovations needed to manage them.